Drug profile · INN
olaparib
LYNPARZA
olaparib (LYNPARZA) is a parp 1, 2 and 3 inhibitor. Associated with AstraZeneca. Route of administration: oral. Current US regulatory status: approved.
Drug details — olaparib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 52
- Data quality
- 0.84
Quick answer
olaparib (LYNPARZA) is a parp 1, 2 and 3 inhibitor. Associated with AstraZeneca. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
PARP 1, 2 and 3 inhibitor
Primary target: PARP 1, 2 and 3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is olaparib?
olaparib (LYNPARZA) is a parp 1, 2 and 3 inhibitor. Associated with AstraZeneca. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for olaparib?
LYNPARZA is a marketed brand name for olaparib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of olaparib?
olaparib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.